Home » Posts tagged with » David A. Ricks
Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA

Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA

The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly and Company (Lilly) for the treatment of mild to moderate Covid-19. Bamlanivimab has been authorized to be used in adults and pediatric patients, aged 12 years and older with a […]

Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt

Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, an investigational neutralizing antibody for the treatment of Covid-19. LY-CoV555 is the first antibody candidate to come out from Lilly’s collaboration with AbCellera Biologics, which was announced in March this […]

Continue reading …
Lilly to build $470m pharma manufacturing plant in North Carolina

US pharma giant Eli Lilly and Company (Lilly) will build a new pharma manufacturing plant in North Carolina with an investment of more than $470 million for producing injectable products and delivery devices. The new Lilly pharma manufacturing facility will be built in Research Triangle Park, and will generate over 460 new jobs in Durham. […]

Continue reading …